JP2023535443A5 - - Google Patents
Info
- Publication number
- JP2023535443A5 JP2023535443A5 JP2023504620A JP2023504620A JP2023535443A5 JP 2023535443 A5 JP2023535443 A5 JP 2023535443A5 JP 2023504620 A JP2023504620 A JP 2023504620A JP 2023504620 A JP2023504620 A JP 2023504620A JP 2023535443 A5 JP2023535443 A5 JP 2023535443A5
- Authority
- JP
- Japan
- Prior art keywords
- complex
- antibody
- composition
- molecular payload
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2026002189A JP2026077638A (ja) | 2020-07-23 | 2026-01-08 | 抗トランスフェリン受容体(TfR)抗体およびその使用 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063055721P | 2020-07-23 | 2020-07-23 | |
| US63/055,721 | 2020-07-23 | ||
| US202063069071P | 2020-08-23 | 2020-08-23 | |
| US63/069,071 | 2020-08-23 | ||
| US202163143825P | 2021-01-30 | 2021-01-30 | |
| US63/143,825 | 2021-01-30 | ||
| PCT/US2021/040984 WO2022020105A1 (en) | 2020-07-23 | 2021-07-09 | Anti-transferrin receptor (tfr) antibody and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026002189A Division JP2026077638A (ja) | 2020-07-23 | 2026-01-08 | 抗トランスフェリン受容体(TfR)抗体およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023535443A JP2023535443A (ja) | 2023-08-17 |
| JP2023535443A5 true JP2023535443A5 (cg-RX-API-DMAC7.html) | 2024-07-17 |
| JP7803925B2 JP7803925B2 (ja) | 2026-01-21 |
Family
ID=79729848
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023504620A Active JP7803925B2 (ja) | 2020-07-23 | 2021-07-09 | 抗トランスフェリン受容体(TfR)抗体およびその使用 |
| JP2026002189A Pending JP2026077638A (ja) | 2020-07-23 | 2026-01-08 | 抗トランスフェリン受容体(TfR)抗体およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026002189A Pending JP2026077638A (ja) | 2020-07-23 | 2026-01-08 | 抗トランスフェリン受容体(TfR)抗体およびその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230256112A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4185315A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7803925B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230041760A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116348138A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021312708A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023001005A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3186727A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL299667A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023000962A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022020105A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US12370264B1 (en) | 2018-08-02 | 2025-07-29 | Dyne Therapeutics, Inc. | Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject |
| US12097263B2 (en) | 2018-08-02 | 2024-09-24 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| EP3830259A4 (en) | 2018-08-02 | 2022-05-04 | Dyne Therapeutics, Inc. | MUSCLE TARGETED COMPLEXES AND THEIR USES IN THE TREATMENT OF FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY |
| WO2020028832A1 (en) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| WO2021154477A1 (en) | 2020-01-31 | 2021-08-05 | Dyne Therapeutics, Inc. | Anti-transferrin receptor (tfr) antibody and uses thereof |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| AU2021313058A1 (en) * | 2020-07-23 | 2023-03-30 | Dyne Therapeutics, Inc. | Muscle-targeting complexes and uses thereof |
| US11633498B2 (en) | 2021-07-09 | 2023-04-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11672872B2 (en) | 2021-07-09 | 2023-06-13 | Dyne Therapeutics, Inc. | Anti-transferrin receptor antibody and uses thereof |
| MX2023000984A (es) * | 2020-07-23 | 2023-05-03 | Dyne Therapeutics Inc | Complejos dirigidos al musculo y usos de los mismos para el tratamiento de distrofinopatias. |
| WO2023283623A1 (en) | 2021-07-09 | 2023-01-12 | Dyne Therapeutics, Inc. | Muscle targeting complexes and formulations for treating dystrophinopathies |
| CA3230796A1 (en) | 2021-09-01 | 2023-03-09 | Biogen Ma Inc. | Anti-transferrin receptor antibodies and uses thereof |
| IL316143A (en) | 2022-04-15 | 2024-12-01 | Dyne Therapeutics Inc | Muscle targeting complexes and formulations for the treatment of myotonic dystrophy |
| CN120659627A (zh) * | 2022-07-29 | 2025-09-16 | 瑞泽恩制药公司 | 用于转铁蛋白受体(tfr)介导的脑和肌肉递送的组合物和方法 |
| US20260015409A1 (en) * | 2022-09-20 | 2026-01-15 | Dana-Farber Cancer Institute, Inc. | Receptor-mediated endocytosis for targeted internalization and degradation of membrane proteins and cargos |
| KR20260044219A (ko) | 2023-07-21 | 2026-04-01 | 매로우 테라퓨틱스, 인크. | 조혈 세포 표적화 접합체 및 관련 방법 |
| IL327952A (en) * | 2023-10-26 | 2026-06-01 | Biogen Ma Inc | Anti-transferrin receptor antibodies and uses thereof |
| WO2025140522A1 (en) * | 2023-12-29 | 2025-07-03 | Nona Biosciences (Suzhou) Co., Ltd. | Anti-tfr1 antibodies, preparation methods and uses thereof |
| CN119192378B (zh) * | 2024-10-16 | 2025-10-17 | 中国人民解放军军事科学院军事医学研究院 | 一种pH敏感型人源抗转铁蛋白受体1抗体 |
| CN119161483B (zh) * | 2024-10-16 | 2026-02-06 | 中国人民解放军军事科学院军事医学研究院 | 人源抗转铁蛋白受体1抗体及其应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8734799B2 (en) * | 2010-04-13 | 2014-05-27 | The Regents Of The University Of California | Unconjugated anti-TfR antibodies and compositions thereof for the treatment of cancer |
| SG11201509566RA (en) * | 2013-05-20 | 2015-12-30 | Genentech Inc | Anti-transferrin receptor antibodies and methods of use |
| CA2990785C (en) | 2015-06-24 | 2024-11-12 | Jcr Pharmaceuticals Co., Ltd. | ANTI-HUMAN TRANSFERRIN RECEPTOR ANTIBODIES CROSSING THE BLOOD-BRAIN BARRIER |
| FR3049951A1 (fr) * | 2016-04-12 | 2017-10-13 | Univ Rabelais Francois | Nouvelles constructions peptidiques et leur utilisation dans le traitement de la toxoplasmose |
| UY38247A (es) * | 2018-05-30 | 2019-12-31 | Novartis Ag | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación |
| EP3829594A4 (en) | 2018-08-02 | 2022-05-11 | Dyne Therapeutics, Inc. | MUSCLE TARGETING COMPLEXES AND THEIR USES FOR THE TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY |
| CN112930193A (zh) * | 2018-08-02 | 2021-06-08 | 达因疗法公司 | 肌肉靶向复合物及其在治疗肌肉萎缩中的用途 |
| IL312067B2 (en) * | 2018-12-21 | 2025-08-01 | Avidity Biosciences Inc | Anti-transferrin receptor antibodies and uses thereof |
-
2021
- 2021-07-09 US US18/017,167 patent/US20230256112A1/en active Pending
- 2021-07-09 CN CN202180064690.5A patent/CN116348138A/zh active Pending
- 2021-07-09 CA CA3186727A patent/CA3186727A1/en active Pending
- 2021-07-09 JP JP2023504620A patent/JP7803925B2/ja active Active
- 2021-07-09 IL IL299667A patent/IL299667A/en unknown
- 2021-07-09 AU AU2021312708A patent/AU2021312708A1/en active Pending
- 2021-07-09 EP EP21846109.3A patent/EP4185315A4/en active Pending
- 2021-07-09 BR BR112023001005A patent/BR112023001005A2/pt unknown
- 2021-07-09 KR KR1020237005829A patent/KR20230041760A/ko active Pending
- 2021-07-09 WO PCT/US2021/040984 patent/WO2022020105A1/en not_active Ceased
- 2021-07-09 MX MX2023000962A patent/MX2023000962A/es unknown
-
2026
- 2026-01-08 JP JP2026002189A patent/JP2026077638A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12121527B2 (en) | Anthracycline-based antibody drug conjugates having high in vivo tolerability | |
| JP2023511774A5 (cg-RX-API-DMAC7.html) | ||
| US12377144B2 (en) | Methods of treating cancer using multi-specific binding proteins that bind NKG2D, CD16 and a tumor-associated antigen | |
| CN106029083B (zh) | 亲水性抗体-药物偶联物 | |
| US20230073692A1 (en) | Anti-slc34a2 antibodies, antibody drug conjugates, and methods of use thereof | |
| JP2022513420A5 (cg-RX-API-DMAC7.html) | ||
| JP2021516960A5 (cg-RX-API-DMAC7.html) | ||
| JP2012529891A5 (cg-RX-API-DMAC7.html) | ||
| JP2018532715A5 (cg-RX-API-DMAC7.html) | ||
| JP2008515889A5 (cg-RX-API-DMAC7.html) | ||
| JP2026505129A (ja) | 抗cdh17抗体及びその使用 | |
| WO2022001710A1 (zh) | 用于抗体与药物偶联体(adc)制备的中间体及其制备方法和应用 | |
| JP2025539702A (ja) | 肥満症を治療する方法 | |
| US20110142756A1 (en) | Method And Composition For The Treatment Of Cancer By The Enzymatic Conversion Of Soluble Radioactive Toxic Precipitates In The Cancer | |
| CN108452319A (zh) | 靶向cd20的抗体偶联药物制剂 | |
| TW201905000A (zh) | 含有抗globo h抗體之抗體-藥物共軛物及其用途 | |
| KR20250009592A (ko) | 항-가변 muc1* 항체 및 그의 용도 | |
| JP2025506248A5 (cg-RX-API-DMAC7.html) | ||
| CN109414509B (zh) | 使用双特异性抗体的抗体药物偶联物平台 | |
| JP2009529915A5 (cg-RX-API-DMAC7.html) | ||
| WO2018232164A1 (en) | Antibody drug conjugates that bind lgr5 | |
| IL310175A (en) | Methods for treating non-muscle invasive bladder cancer (NMIBC) with antibody-drug conjugates (ADC) that bind to 191P4D12 proteins | |
| CN1946740B (zh) | 抗人腱生蛋白单克隆抗体 | |
| CN119868576A (zh) | 用于制备抗体与药物偶联物的中间体及其制备方法和应用 | |
| US7615221B2 (en) | Compositions and methods for treating cancer |